| payload |
{"created_at":"2026-04-07T23:23:54.391 {"created_at":"2026-04-07T23:23:54.391414+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:0f072cc71fa28b97","evidence_event_ids":["evt_d9514a2c4bcc"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt","as_of":"2026-04-07T23:23:54.391414+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt","company":"Cartesian Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt","article_chars":3120,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_aa49e6dc5791ee39","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt","content_type":"text/plain","enriched_at":"2026-04-07T23:57:21.151713+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt","source_event_id":"evt_d9514a2c4bcc","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"3c39a1d53bdce42d","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-02","2026-04-06","2026-04-07T23:23:54.391414+00:00","2023-11-13","2009-01-09"],"entities":[{"asset_class":"equity","name":"Cartesian Therapeutics, Inc.","relevance":"high","symbol":"RNAC","type":"issuer"},{"asset_class":"equity","name":"Seven One Eight Three Four Irrevocable Trust","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"Hoge Elizabeth","relevance":"medium","symbol":"","type":"reporting_owner"}],"event_type":"listing","information_gaps":["The cleaned text does not clearly provide the full before/after beneficial ownership totals beyond the transaction lines shown; exact net change in holdings is not explicitly summarized.","The signal headline mentions \u201cRNAC filed 4,\u201d but the provided text does not explicitly state the ticker symbol; it only identifies the issuer as Cartesian Therapeutics, Inc.","The specific beneficial ownership limitation threshold is not provided in the excerpt.","The exact number of preferred shares converted vs remaining is only partially inferable from the transaction lines shown; a complete reconciliation is not explicitly stated."],"key_facts":["SEC Form 4 filed for Cartesian Therapeutics, Inc. (issuer) with conforming period of report 2026-04-02 and filed as of 2026-04-06.","Reporting owners include Seven One Eight Three Four Irrevocable Trust (trustee) and Hoge Elizabeth (trust-related reporting person).","The filing states: \u201cOn April 2, 2026, Seven One Eight Three Four Irrevocable Trust\u2026 elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock.\u201d","The filing states the remaining Series A Non-Voting Convertible Preferred Stock held by the Trust is \u201csubject to a beneficial ownership limitation.\u201d","The filing states the securities represent \u201cmerger consideration payable as a result of the closing of the Merger and securities purchased in a private placement in November 2023.\u201d","The filing references an Agreement and Plan of Merger dated November 13, 2023 and that the issuer acquired a private Delaware corporation then known as Cartesian Therapeutics, Inc. on November 13, 2023.","Signature dated 2026-04-06 by an authorized person (\"/s/ Murat Kalayoglu\")."],"numeric_claims":[{"label":"Conversion date","value":"2026-04-02"},{"label":"Filed as of date","value":"2026-04-06"},{"label":"Series A Non-Voting Convertible Preferred Stock converted (shares shown)","value":"22740.03"},{"label":"Common stock acquired/shown (shares shown)","value":"758001"},{"label":"Common stock (additional line shown)","value":"33662.224"},{"label":"Series A Non-Voting Convertible Preferred Stock (additional line shown)","value":"22740.03"}],"primary_claim":"On April 2, 2026, Seven One Eight Three Four Irrevocable Trust converted part of its Cartesian Therapeutics Series A Non-Voting Convertible Preferred Stock into Cartesian common stock, with remaining preferred subject to a beneficial ownership limitation.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Cartesian Therapeutics, Inc. reported Form 4 filings showing that on April 2, 2026, Seven One Eight Three Four Irrevocable Trust elected to convert a portion of its Series A Non-Voting Convertible Preferred Stock into common stock. The filing also identifies the reporting person as a trustee and references merger/private placement consideration.","topics":["SEC Form 4","beneficial ownership","conversion of preferred to common","Series A Non-Voting Convertible Preferred Stock","common stock","merger consideration","private placement"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Cartesian Therapeutics, Inc. \u00b7 Filed 20260406","ticker":"RNAC","tickers":["RNAC"],"title":"RNAC filed 4","url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt"}}... |